Skip to main content

Deferoxamine Disease Interactions

There are 5 disease interactions with deferoxamine.

Major

Deferoxamine (applies to deferoxamine) renal dysfunction

Major Potential Hazard, High plausibility.

The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria. Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.

References

  1. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals
Moderate

Deferoxamine (applies to deferoxamine) auditory dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Hearing Loss

Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels. Therapy with deferoxamine should be administered cautiously in patients with hearing impairment. Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.

References

  1. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals
Moderate

Deferoxamine (applies to deferoxamine) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No studies of deferoxamine have been performed in patients with hepatic impairment. Caution is advised.

References

  1. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals
Moderate

Deferoxamine (applies to deferoxamine) ocular dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Visual Defect/Disturbance

Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision. Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels. Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects. Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy. Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.

References

  1. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals
Moderate

Deferoxamine (applies to deferoxamine) respiratory distress syndrome

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thalassemia

Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine. Caution is recommended when using deferoxamine in these patients.

References

  1. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals

Deferoxamine drug interactions

There are 33 drug interactions with deferoxamine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer